Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Inventory (2016 - 2025)

Sanofi (SNY) has disclosed Inventory for 11 consecutive years, with $11.9 billion as the latest value for Q4 2025.

  • Quarterly Inventory rose 17.98% to $11.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 billion through Dec 2025, up 17.98% year-over-year, with the annual reading at $11.5 billion for FY2025, 13.05% up from the prior year.
  • Inventory hit $11.9 billion in Q4 2025 for Sanofi, up from $10.1 billion in the prior quarter.
  • In the past five years, Inventory ranged from a high of $11.9 billion in Q4 2025 to a low of $9.1 billion in Q4 2022.
  • Historically, Inventory has averaged $10.3 billion across 5 years, with a median of $10.1 billion in 2024.
  • Biggest five-year swings in Inventory: dropped 8.31% in 2022 and later grew 17.98% in 2025.
  • Year by year, Inventory stood at $10.0 billion in 2021, then decreased by 8.31% to $9.1 billion in 2022, then grew by 13.77% to $10.4 billion in 2023, then dropped by 3.1% to $10.1 billion in 2024, then increased by 17.98% to $11.9 billion in 2025.
  • Business Quant data shows Inventory for SNY at $11.9 billion in Q4 2025, $10.1 billion in Q4 2024, and $10.4 billion in Q4 2023.